Literature DB >> 14683452

Risk assessment of the use of autonomous parvovirus-based vectors.

Francis Dupont1.   

Abstract

Autonomous parvoviruses are small, non-enveloped, lytic DNA viruses replicating in the nucleus of actively dividing mammalian cells of appropriate species and tissue origins. In contrast to AAV, the other main subgroup of parvoviruses, autonomous parvoviruses do not require the assistance of an auxiliary virus for productive infection and do not stably integrate in the cellular DNA. Therefore, autonomous parvoviruses are suitable vectors for mediating transient gene transduction in dividing target cells. Interestingly, some of these viruses possess a striking inherent oncotropism, which may render them particularly suitable as selective vehicles in the clinical context of cancer gene therapy. In this chapter, we will present a brief overview of the biology of autonomous parvoviruses. This topic will be followed by a description of the design and recent developments in the production and use of parvoviral vectors, with a particular emphasis on biosafety aspects. Finally, the risk assessment related to the production and use of parvoviral vectors will be discussed in last part of the chapter.

Entities:  

Mesh:

Year:  2003        PMID: 14683452     DOI: 10.2174/1566523034578104

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  9 in total

1.  The parvoviral capsid controls an intracellular phase of infection essential for efficient killing of stepwise-transformed human fibroblasts.

Authors:  Justin Paglino; Peter Tattersall
Journal:  Virology       Date:  2011-05-20       Impact factor: 3.616

2.  Viral Vector Biosafety in Laboratory Animal Research.

Authors:  Dalis E Collins; Jon D Reuter; Howard G Rush; Jason S Villano
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

3.  Structures of minute virus of mice replication initiator protein N-terminal domain: Insights into DNA nicking and origin binding.

Authors:  Sunil K Tewary; Lingfei Liang; Zihan Lin; Annie Lynn; Susan F Cotmore; Peter Tattersall; Haiyan Zhao; Liang Tang
Journal:  Virology       Date:  2014-12-18       Impact factor: 3.616

4.  Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses.

Authors:  Ellen M Vollmers; Peter Tattersall
Journal:  Virology       Date:  2013-08-09       Impact factor: 3.616

5.  LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.

Authors:  Justin C Paglino; Koray Ozduman; Anthony N van den Pol
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

Review 6.  Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges.

Authors:  Sumit Ghosh; Alex M Brown; Chris Jenkins; Katie Campbell
Journal:  Appl Biosaf       Date:  2020-03-01

7.  Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.

Authors:  Justin C Paglino; Wells Andres; Anthony N van den Pol
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 8.  Best of most possible worlds: Hybrid gene therapy vectors based on parvoviruses and heterologous viruses.

Authors:  Julia Fakhiri; Dirk Grimm
Journal:  Mol Ther       Date:  2021-04-05       Impact factor: 11.454

9.  Genome sequence of tumor virus x, a member of the genus protoparvovirus in the family parvoviridae.

Authors:  Ellen M Vollmers; Anthony D'Abramo; Susan F Cotmore; Peter Tattersall
Journal:  Genome Announc       Date:  2014-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.